108 bioequivalence tests approved by KFDA in first half

The Korea Food and Drug Administration said Wednesday that it approved a total of 108 bioequivalence tests in the first half of this year, showing a decrease compared to 114 cases from a year earlier.

By therapeutic category, antihypertensive agents, such as Novartis’s Exforge (valsartan+amlopdipine besylate) and Merck’s Cozaar Plus (losartan calcium + hydrochlorozide), led any others with...